MedWatch

BMS’ takeover decision looms after ”overwhelming” data from Galecto

Galecto Biotech has presented “ground-breaking” data from a phase II study with a candidate it partnered with Bristol-Myers Squibb on back in 2014. The clock is now ticking for BMS, which has to decide whether or not to use an option to buy the Denmark-based biotech.

Photo: Hans Schambye

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

FDA vil lette vejen til markedet for medicin mod Alzheimers

De amerikanske lægemiddelmyndigheder vil lempe kravene til godkendelse af lægemidler mod Alzheimers, fordi forskning viser, at sygdommen indtræder tidligere end hidtil antaget. Lægemiddeludviklingen og godkendelse heraf derfor skal tilpasses derefter, mener FDA-boss Scott Gottlieb.

Related articles